Licensing & Partnerships
Evgen is open to out-licensing and collaboration discussions on all of its programmes and is seeking to expand its pipeline through in-licensing or partnerships.
Please contact us for more information.
Evgen has licensed the global rights for lead asset SFX‐01 in neurodevelopmental disorders and schizophrenia to Stalicla.
Stalicla will use its proprietary precision medicine platform to identify specific phenotypes of autism spectrum disorder (ASD). Evgen and Stalicla will collaborate initially on a clinical programme in ASD, with Stalicla funding all clinical development activities.
Evgen retains the global rights for all other indications.
Evgen has licensed Sulforadex®, its sulforaphane stabilisation technology, in a number of non-pharmaceutical applications to Juvenescence Ltd.
Juvenescence will deploy the Sulforadex® stabilisation technology to manufacture and market a nutritional health product containing a defined and stable dose of naturally derived sulforaphane. Launch is expected within the next two years.